Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).

2. Male (who have more serious effects due to the X chromosome nature of the disorder)

3. Age 13-29 years.

4. Parent of adolescent must be willing to sign informed consent.

5. Intelligence Quotient (IQ) > 42.

Exclusion Criteria:

1. Cardiac risk factors.

2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or atypical antipsychotics.